Valuation : Sionna Therapeutics, Inc.

Market Cap 331M 285M 269M 245M 457M 31.22B 461M 3.18B 1.23B 15.96B 1.24B 1.21B 52.44B P/E 2026 *
-2.97x
P/E 2027 * -3.11x
Enterprise Value 184M 159M 150M 137M 255M 17.42B 257M 1.77B 688M 8.9B 692M 677M 29.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Sionna Therapeutics, Inc.

1 day+13.16%
1 week+18.48%
Current month+21.23%
1 month-84.49%
3 months-79.96%
6 months-78.45%
Current year-82.23%
1 week 5.75
Extreme 5.75
7.35
1 month 4.01
Extreme 4.01
54.97
Current year 4.01
Extreme 4.01
54.97
1 year 4.01
Extreme 4.01
54.97
3 years 4.01
Extreme 4.01
54.97
5 years 4.01
Extreme 4.01
54.97
10 years 4.01
Extreme 4.01
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 01/08/2019
Corporate Officer/Principal - 01/08/2019
Chief Executive Officer 55 01/05/2021
Director TitleAgeSince
Director/Board Member 51 01/12/2019
Director/Board Member 44 01/12/2019
Director/Board Member 52 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
07/07/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
06/07/26 Exercice

General Counsel

30,750 0.0681%
Change 5-day change 1-year change 3-year change Capi.($)
+13.16%+18.48%-71.21% - 331M
+0.22%-0.85%+2.24%+17.79% 50.14B
-0.30%-2.88%+429.29%+496.95% 44.85B
+2.13%+0.89%+43.59%+17.61% 43.43B
+0.87%-3.73%+8.96%+73.17% 41.14B
-0.90%-3.67%+14.26%+48.44% 32.92B
+2.71%+6.82% - - 17.56B
+1.68%-4.20%+25.28%+116.83% 16.55B
+1.10%+0.79%+17.05%+29.50% 14.65B
+3.34%-1.13%+80.94%+39.19% 13.93B
Average +2.40%+1.08%+61.16%+104.93% 27.55B
Weighted average by Cap. +0.87%-1.19%+92.54%+122.12%

Financials

2026 *2027 *
Net sales - -
Net income -112M -96.93M -91.31M -83.19M -155M -10.61B -157M -1.08B -420M -5.43B -422M -413M -17.83B -116M -100M -94.24M -85.86M -160M -10.95B -162M -1.12B -433M -5.6B -435M -426M -18.4B
Net Debt -146M -126M -119M -108M -202M -13.81B -204M -1.41B -546M -7.06B -549M -537M -23.19B -183M -158M -149M -135M -253M -17.27B -255M -1.76B -683M -8.83B -686M -671M -29B
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
02/09/26 $7.310 +13.16% 1,590,547
01/09/26 $6.460 +7.13% 1,411,953
31/08/26 $6.030 +2.73% 1,383,775
28/08/26 $5.870 -3.14% 784,785
27/08/26 $6.060 -1.78% 775,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
7.310USD
Average target price
15.17USD
Spread / Average Target
+107.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SION Stock